Jan Berka, Ph.D.

Head of Biomarker Technologies group, Roche sequencing solutions, Roche Molecular Systems, Pleasanton, USA

 

Frantisek Foret, Ph.D.

Director of the Institute of Analytical Chemistry of the CAS, v. v. i., Brno, Czech Republic

​

Tomáš Büchler, M.D., Ph.D.

Head of the Department of Oncology, 

2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

​

Filip Janku, M.D., Ph.D.

Associate Professor, Department of Investigational Cancer Therapeutics,
Division of Cancer Medicine, The University of Texas, MD Anderson Cancer
Center, Houston, USA
Chief Medical Officer, Monte Rosa Therapeutics, Inc., Boston, USA

 

Igor Kiss, M.D., Ph.D.

Deputy Head of the Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic

 

Milan Macek, M.D., Ph.D.

Head of the Institute of Biology and Molecular Genetics, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

 

Lubos Petruzelka, M.D., Ph.D.

Head of the Department of Oncology, 

1st Faculty of Medicine, Charles University, General University Hospital and Military University Hospital, Prague, Czech Republic

 

Ales Ryska, M.D., Ph.D.

Head of the Fingerland department of Pathology, Faculty of Medicine in Hradec Kralove, Charles University and University Hospital Hradec Kralove, Czech Republic

​

Miroslav Ryska, M.D., Ph.D.

(in memoriam)

Head of the Department of Surgery, 2nd Faculty of Medicine, Charles University and Military University Hospital, Prague, Czech Republic

​